Microfluidic Chip for Rapid Antibiotic Susceptibility Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic processes for antibiotic-resistant bacteria are slow due to the need for bacterial culture growth and antibiotic testing, often requiring days to determine the appropriate antibiotic treatment, leading to initial general antibiotic use that may not be effective.
Innovation Solution
A microfluidic testing system that processes biological samples in parallel and serial stages to rapidly identify bacteria and determine the optimal antibiotic and dosage by using affinity labels and reagents on a microchip, enabling point-of-care testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional bacterial culture and antibiotic testing methods are used, then accurate identification of bacteria and determination of effective antibiotics can be achieved, but the testing process takes 2-3 days which delays treatment
Solution Approach 1:
The testing process is divided into multiple parallel stages on the microfluidic chip: initial bacterial exposure to antibiotics, intermediate observation of bacterial responses, and sequential testing with different antibiotics. Each stage processes different aspects of the testing simultaneously, reducing overall time while maintaining accuracy through systematic segmentation of the diagnostic workflow.
Solution Approach 2:
The patent transitions from traditional two-dimensional petri dish culture to a three-dimensional microfluidic chip environment with multiple stacked layers and channels. This dimensional change enables parallel processing of multiple antibiotic tests simultaneously within a compact space, dramatically reducing testing time from days to hours while preserving measurement precision through controlled microenvironment conditions.
2Reliability
If general antibiotics are prescribed initially to ensure coverage, then patient safety is improved, but treatment effectiveness is reduced due to potential mismatch with the specific bacteria
Solution Approach 1:
The microfluidic chip performs preliminary antibiotic susceptibility testing before final treatment decisions are made. By pre-exposing bacteria to multiple antibiotics in parallel and observing responses in real-time, the system provides advance information about which antibiotics will be effective, allowing clinicians to prescribe targeted treatment from the start rather than relying on broad-spectrum empiric therapy.
Solution Approach 2:
The system implements continuous feedback by monitoring bacterial responses to antibiotics in real-time through the microfluidic channels. Optical sensors detect changes in bacterial viability and morphology as antibiotics are introduced sequentially, providing immediate feedback about which antibiotics are effective. This feedback loop enables rapid adjustment of treatment strategy based on actual bacterial susceptibility rather than statistical probability.
Data Source
AI summary
A method for generating medical trends based on medical test results by a server, comprising obtaining results from a first test related to a medical condition of a first patient, obtaining results from a second test related to a medical condition second patient, wherein the results include patient information and efficacy and dosage level information of a medication, comparing the patient information and the test results of the first patient with the patient information and the test results of the second patient, determining that a patient characteristic of the first patient matches a patient characteristic of the second patient, storing a potential trend, receiving a plurality of additional test results, determining that the potential trend is found in the additional test results in an amount that is above a threshold, and altering the potential trend to an active trend.